Studies related to Myeloperoxidase and L-Carnitine

L-Carnitine Supplementation Reduces Biomarkers Of Inflammatory And Oxidative Stress In Patients With Coronary Artery Disease: A Randomised Controlled Trial

Effect Decrease
Values nmol.L. Placebo: before 1.16 (0.41), after 1.3 (0.48). Carnitine: before 1.1 (0.5), after 0.94 (0.47).
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 75
Sex Both Genders
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 75 participants with coronary artery disease took 1000 mg of L-carnitine or placebo daily for 12 weeks.

The carnitine group saw a statistically significant increase in lean body mass and reduction in body fat mass and systolic blood pressure, whereas the placebo group didn't see a statistically significant difference. The placebo group saw a statistically significant reduction in diastolic blood pressure, whereas the L-carnitine group didn't. There weren't statistically significant differences for weight or BMI.

The carnitine group saw a statistically significant increase in total antioxidant capacity and reduction in nitrotyrosine, myeloperoxidase, and c-reactive protein. In contrast, the placebo group didn't see a statistically significant difference and generally saw a worsening.